CALT Annual CFF
$18.86 M
-$38.57 M-67.16%
31 December 2023
Summary:
As of January 22, 2025, CALT annual cash flow from financing activities is $18.86 million, with the most recent change of -$38.57 million (-67.16%) on December 31, 2023. During the last 3 years, it has fallen by -$65.09 million (-77.54%).CALT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CALT Quarterly CFF
-$364.70 K
+$162.40 K+30.81%
30 June 2024
Summary:
As of January 22, 2025, CALT quarterly cash flow from financing activities is -$364.70 thousand, with the most recent change of +$162.40 thousand (+30.81%) on June 30, 2024. Over the past year, it has increased by +$162.40 thousand (+30.81%).CALT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CALT TTM CFF
$18.54 M
-$80.00 K-0.43%
30 June 2024
Summary:
As of January 22, 2025, CALT TTM cash flow from financing activities is $18.54 million, with the most recent change of -$80.00 thousand (-0.43%) on June 30, 2024. Over the past year, it has dropped by -$80.00 thousand (-0.43%).CALT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CALT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -67.2% | +30.8% | -0.4% |
| 3 y3 years | -77.5% | -105.7% | -68.3% |
| 5 y5 years | -77.2% | -2468.3% | -11.9% |
CALT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -77.5% | -100.4% | -81.7% |
Calliditas Therapeutics AB (Publ) Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$364.70 K(-30.8%) | $18.54 M(-0.4%) |
| Mar 2024 | - | -$527.10 K(-102.7%) | $18.62 M(-1.3%) |
| Dec 2023 | $18.86 M(-67.2%) | $19.68 M(-7881.8%) | $18.86 M(-34.1%) |
| Sept 2023 | - | -$252.90 K(-11.2%) | $28.63 M(+7.6%) |
| June 2023 | - | -$284.70 K(-0.1%) | $26.61 M(-47.5%) |
| Mar 2023 | - | -$284.90 K(-101.0%) | $50.70 M(-11.7%) |
| Dec 2022 | $57.43 M(+13.0%) | $29.45 M(-1400.2%) | $57.43 M(+142.8%) |
| Sept 2022 | - | -$2.26 M(-109.5%) | $23.66 M(-71.3%) |
| June 2022 | - | $23.80 M(+269.1%) | $82.32 M(+40.9%) |
| Mar 2022 | - | $6.45 M(-249.1%) | $58.44 M(+14.9%) |
| Dec 2021 | $50.84 M(-39.4%) | -$4.32 M(-107.7%) | $50.84 M(+17.3%) |
| Sept 2021 | - | $56.40 M(<-9900.0%) | $43.34 M(+1808.3%) |
| June 2021 | - | -$80.80 K(-93.0%) | $2.27 M(-97.3%) |
| Mar 2021 | - | -$1.15 M(-90.3%) | $84.20 M(+0.3%) |
| Dec 2020 | $83.95 M | -$11.83 M(-177.2%) | $83.95 M(-12.5%) |
| Sept 2020 | - | $15.33 M(-81.3%) | $95.95 M(-5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | $81.85 M(-5940.2%) | $101.53 M(+416.3%) |
| Mar 2020 | - | -$1.40 M(-902.2%) | $19.66 M(-6.6%) |
| Dec 2019 | $21.05 M(-74.5%) | $174.70 K(-99.2%) | $21.05 M(-10.7%) |
| Sept 2019 | - | $20.90 M(<-9900.0%) | $23.58 M(-70.2%) |
| June 2019 | - | -$14.20 K(+0.7%) | $79.06 M(+0.2%) |
| Mar 2019 | - | -$14.10 K(-100.5%) | $78.90 M(-4.4%) |
| Dec 2018 | $82.56 M(+595.1%) | $2.70 M(-96.5%) | $82.56 M(-5.0%) |
| Sept 2018 | - | $76.38 M(<-9900.0%) | $86.93 M(+671.7%) |
| June 2018 | - | -$165.90 K(-104.6%) | $11.26 M(-27.4%) |
| Mar 2018 | - | $3.65 M(-48.4%) | $15.52 M(+30.7%) |
| Dec 2017 | $11.88 M(+85.5%) | $7.06 M(+880.4%) | $11.88 M(+146.8%) |
| Sept 2017 | - | $720.60 K(-82.4%) | $4.81 M(+17.6%) |
| June 2017 | - | $4.09 M(>+9900.0%) | $4.09 M(>+9900.0%) |
| Mar 2017 | - | $0.00 | $0.00 |
| Dec 2016 | $6.40 M(-2.2%) | - | - |
| Dec 2015 | $6.55 M | - | - |
FAQ
- What is Calliditas Therapeutics AB (publ) annual cash flow from financing activities?
- What is the all time high annual CFF for Calliditas Therapeutics AB (publ)?
- What is Calliditas Therapeutics AB (publ) annual CFF year-on-year change?
- What is Calliditas Therapeutics AB (publ) quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Calliditas Therapeutics AB (publ)?
- What is Calliditas Therapeutics AB (publ) quarterly CFF year-on-year change?
- What is Calliditas Therapeutics AB (publ) TTM cash flow from financing activities?
- What is the all time high TTM CFF for Calliditas Therapeutics AB (publ)?
- What is Calliditas Therapeutics AB (publ) TTM CFF year-on-year change?
What is Calliditas Therapeutics AB (publ) annual cash flow from financing activities?
The current annual CFF of CALT is $18.86 M
What is the all time high annual CFF for Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ) all-time high annual cash flow from financing activities is $83.95 M
What is Calliditas Therapeutics AB (publ) annual CFF year-on-year change?
Over the past year, CALT annual cash flow from financing activities has changed by -$38.57 M (-67.16%)
What is Calliditas Therapeutics AB (publ) quarterly cash flow from financing activities?
The current quarterly CFF of CALT is -$364.70 K
What is the all time high quarterly CFF for Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ) all-time high quarterly cash flow from financing activities is $81.85 M
What is Calliditas Therapeutics AB (publ) quarterly CFF year-on-year change?
Over the past year, CALT quarterly cash flow from financing activities has changed by +$162.40 K (+30.81%)
What is Calliditas Therapeutics AB (publ) TTM cash flow from financing activities?
The current TTM CFF of CALT is $18.54 M
What is the all time high TTM CFF for Calliditas Therapeutics AB (publ)?
Calliditas Therapeutics AB (publ) all-time high TTM cash flow from financing activities is $101.53 M
What is Calliditas Therapeutics AB (publ) TTM CFF year-on-year change?
Over the past year, CALT TTM cash flow from financing activities has changed by -$80.00 K (-0.43%)